Latest news with #CRISP
Time of India
2 days ago
- Business
- Time of India
Moving beyond SMART goals: The emergence of CRISP goals in strategic leadership, ETHRWorld
Performance Management 4 min read Moving beyond SMART goals: The emergence of CRISP goals in strategic leadership In boardrooms and team huddles worldwide, SMART goals—Specific, Measurable, Achievable, Relevant, Time-bound—have long been the gold standard for driving performance. But in today's hyper-dynamic business landscape, critics argue that SMART falls short; it is too narrow to spark ambition, too rigid to adapt, and often too transactional to inspire. Enter CRISP goals—a fresh framework designed to inject challenge, robustness, inspiration, strategy and rigorous planning into every target we set. The article introduces the CRISP framework—Challenging, Robust, Inspirational, Strategic, and Planned—as a forward-thinking alternative that addresses modern leadership and organizational needs. By analysing the limitations of SMART goals and demonstrating the advantages of CRISP goals, it highlights why companies must adopt a more visionary and resilient approach to goal-setting.
Yahoo
03-06-2025
- Business
- Yahoo
Gene Editing Market Research Report 2025-2029 - Biotech Leaders Drive Innovation as Gene Editing Becomes Key to Sustainable Solutions
Gene editing technologies like CRISPR are revolutionizing biotechnology, expanding from medical applications to diverse industries. Initially used for altering genes in human cells to cure previously uncurable diseases, they are now paving the way for rapid growth and new industrial applications. Discover the emerging opportunities, near and long-term expectations, and growth potential through comprehensive research that empowers you as an expert in your field. Complimentary additional data is available. Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Markets 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides" report has been added to offering. This comprehensive view of the gene editing landscape highlights the technology's potential to drive transformative change. As breakthroughs become more frequent, businesses need to stay informed about the latest trends and projections. Those equipped with thorough market insights are poised to leverage these technologies effectively, ensuring competitive advantages in their respective fields. Gene Editing is moving from strength to strength. CRISPR and similar tools are finding new uses in every area of biotechnology. It started with Medical applications by changing genes in living human cells. Uncurable diseases have already being cured. More are on the way. The market for gene editing tools is witnessing a surge, with rapid growth driven by technological advances. These tools are broadening their reach beyond healthcare, offering groundbreaking possibilities in agriculture, biofuel production, and more. Major players in the biotechnology industry are spearheading research to develop innovative applications, ensuring continual market evolution. Industry experts indicate that the gene editing industry is set to continue its rapid expansion. Companies and researchers are actively investigating diverse opportunities in areas such as crop improvement, pest control, and sustainable resource management. These developments position gene editing as a cornerstone technology, promising significant impacts on global food security and sustainable practices. The gene editing market is becoming increasingly sophisticated, with new applications and technologies emerging regularly. As demand for more precise and efficient biotechnological solutions grows, the sector continues to attract substantial investment. Key players are focusing on research and development, strengthening their market positions, and pushing forward innovations to meet both current needs and future challenges. Key Topics Covered: 1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 Methodology2.1.1 Methodology2.1.2 Sources2.1.3 Authors2.2 What is Gene Editing?2.3 The CRISPR Example2.3.1 What is CRISPR?2.3.2 The CRISPR Family2.4 Chromosomes, Genes and Epigenetics2.4.1 Chromosomes2.4.2 Genes2.4.3 Epigenetics2.5 Market Definition2.5.1 Revenue Market Size2.6 Perspective: Healthcare Spending2.6.1 Global Healthcare Spending2.6.2 Spending on Healthcare and Pharmaceuticals2.6.3 Spending on Diagnostics2.6.4 Important Role of Insurance for Medical Services3 Market Structure3.1 Market Structure Therapeutics3.1.1 Research and Development (R&D) Companies3.1.2 Biotechnology Companies3.1.3 Generic Drug Manufacturers3.1.4 Big Pharmaceuticals3.1.5 Contract Research Organizations (CROs)3.1.6 Contract Manufacturing Organizations (CMOs)3.1.7 Specialty Pharmaceutical Companies3.1.8 Pharmaceutical Distributors3.1.9 Retail Pharmacies3.1.10 Wholesalers3.1.11 Online Pharmacies3.1.12 Health Technology Companies3.1.13 Pharmacy Benefit Managers (PBMs)3.1.14 Clinical Laboratories3.1.15 Medical Device Companies3.1.16 Regulatory Bodies3.2 Market Structure Diagnostics3.2.1 Academic Research Lab3.2.2 Diagnostic Test Developer3.2.3 Instrumentation Supplier3.2.4 Chemical/Reagent Supplier3.2.5 Pathology Supplier3.2.6 Independent Clinical Laboratory3.2.7 Public National/regional Laboratory3.2.8 Hospital Laboratory3.2.9 Physicians Office Lab (POLS)3.2.10 Audit Body3.2.11 Certification Body4 Market Trends4.1 Factors Driving Growth4.1.1 Cell Therapy4.1.2 Gene Therapy4.1.3 The New Agriculture4.1.4 Genetics and Cell Metabolism4.2 Factors Limiting Growth4.2.1 The Cost Curve4.2.2 Time and Trials4.2.3 The Price Barrier5 Recent Developments in Gene Editing5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 CRISPR tool allows for remote-controlled gene-editing5.3 CRISPR Making Sweeter Tomatoes5.4 Researchers Create gene-edited prawns5.5 Gene Editing Corrects Cystic Fibrosis5.6 CRISPR gene editing to change healthcare?5.7 CrisprBits Collaborates With MolBio Diagnostics5.8 Sherlock Bioscience to Launch Free AI-Based Operating System5.9 Sherlock Biosciences to Acquire Sense Biodetection5.10 CRISPR Enzyme Discovery Opens New Applications5.11 Sherlock Biosciences Adds Ambient Amplification to Toolkit5.12 Rice University Adapts CRISPR Enzyme5.13 Princeton Group Develops Cas13 Assay for Point-of-Care Use5.14 Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System5.15 Sherlock Biosciences Raises $80M5.16 Broad Institute Considers CRISPR Respiratory Panels to Replace PCR5.17 Medix Biochemica Acquires MyPols Biotec5.18 Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA5.19 Genome Diagnostics Makes €1M Investment in Scope Biosciences5.20 CRISPR Test Could be used for Asymptomatic Screening5.21 Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test5.22 Pandemic Accelerates Development of CRISPR Diagnostics5.23 ERS Genomics Licenses CRISPR Patents to Vivlion5.24 Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test5.25 ERS Genomics, FASMAC to Commercialize CRISPR-Cas95.26 The Nobel Prize in Chemistry 2020 - CRISPR Wins6 Key Companies6.1 10x Genomics, Inc.6.2 4D Molecular Therapeutics6.3 Abeona Therapeutics6.4 Acrigen Biosciences6.5 Adarx Pharmaceuticals6.6 Adverum Biotechnologies6.7 Affini-T Therapeutics6.8 Agilent6.9 Arbor Biotechnologies6.10 Arcturus Therapeutics6.11 Axxam6.12 Beam Therapeutics6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Binx Health6.16 bioMerieux Diagnostics6.17 Bio-Rad Laboratories, Inc.6.18 Bluebird Bio6.19 Caribou Biosciences6.20 Cell Microsystems6.21 Cellenion (BICO)6.22 Century Therapeutics6.23 Chroma Medicine6.24 Creative Biogene6.25 Crispr Therapeutics6.26 Editas Medicine6.27 ERS Genomics6.28 FASMAC6.29 Genscript Biotech6.30 Illumina6.31 Inscripta6.32 Intellia Therapeutics6.33 J&J Innovative Medicine6.34 Locus Biosciences6.35 Mammoth Biosciences6.36 Metagenomi6.37 Myllia Biotechnology6.38 Namocell6.39 NRGene6.40 Poseida Therapeutics6.41 Precision Biosciences6.42 Prime Medicine6.43 Proof Diagnostics6.44 Regeneron Pharmaceuticals6.45 Revvity6.46 Roche Diagnostics6.47 Sherlock Biosciences6.48 Thermo Fisher Scientific6.49 Twist Bioscience6.50 Verve Therapeutics6.51 Vivlion6.52 Wave Life Science7 The Global Market for Gene Editing7.1 Global Market Overview by Country7.2 Global Market by Application - Overview7.3 Global Market Technology - Overview7.4 Global Market Type - Overview7.5 Global Market Industry - Overview7.6 Global Market Product - Overview8 Gene Editing Markets - By Application8.1 Cell Line8.2 Plant8.3 Animal8.4 Cell Therapy8.5 Gene Therapy8.6 Diagnostics8.7 Research9 Global Gene Editing Markets - by Technology9.1 Crispr9.2 Talens9.3 ZFN9.4 Meganuclease10 Gene Editing Markets - by Place10.1 In Vivo10.2 Ex Vivo10.3 In Vitro11 Gene Editing Markets - by Industry11.1 Pharma11.2 Clinical11.3 Academic11.4 Contract12 Global Gene Editing Markets - by Product12.1 Instruments12.2 Cells12.3 Reagents13 Appendices13.1 United States Medicare System: laboratory Fees Schedule13.2 The Most Used IVD Assays13.3 The Highest Grossing Assays13.4 The Whole Genome Sequence of SARS-CoV-213.5 Global Listing of Sequencing Establishments - Location & Contacts For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Associated Press
25-04-2025
- Business
- Associated Press
High Value Acquisition Completed to Substantially Strengthen Operations Structure and Seasoned Leadership of Advanced Video Compression Tech Company: Reticulate Micro, Inc. (Symbol: RMXI)
$RMXI Proprietary Platform Delivers High-Impact Results in Ultra-Low-Bandwidth Environments, Enabling Real-Time Video Where Traditional Solutions Fail Reticulate Micro, Inc. (OTCQB: RMXI) is a video technology company focused on addressing the world's growing crisis in video data transmission and storage. Through its proprietary VAST (Video Adaptive Systems Technology) platform, RMXI is aiming to transform how organizations capture, transmit, store and share visual data. The Company's battle-tested technology, proven in military applications, reduces video bandwidth, storage, and power consumption by up to 50% while maintaining quality across any network or hardware platform. From defense to AI and enterprise applications, RMXI endeavors to redefine how organizations handle the growing demands of video data worldwide. Reticulate Micro's 2024 was defined by rapid technological advancements and rigorous market validation of its flagship VAST platform. Originally developed for government and defense applications, RMXI VAST delivered high-impact results in ultra-low-bandwidth environments, enabling real-time video where traditional solutions fail. Multiple military exercises and test events (over 20 in 2024) have proven RMXI VAST's ability to stream video on any communication band, including narrow-band SATCOM, L-Band and even legacy HF networks where streaming video was thought to be unviable. Building on its success in tactical video solutions for defense applications, RMXI is expanding its enterprise-level offerings for government and commercial customers. RMXI plans to release significant platform enhancements in early 2025, including advanced dynamic bandwidth management and adaptive encoding capabilities. Additionally, through its commercial joint venture launching in Q1 2025, RMXI is positioned to bring its revolutionary technology to global commercial markets. The RMXI 2025 strategy centers on partner-focused growth and a platform-centric product roadmap: Government Sector Partnership & OEM Integration Strategic Partner Program: RMXI is launching a comprehensive integration program enabling partners and system integrators to embed VAST technology directly into their product lines and existing government contract vehicles. Major Exercises & Evaluations: VAST has already been validated within U.S. Special Operations, multiple U.S. Army and Naval initiatives, and a range of international defense programs. This year's schedule includes high-profile exercises with U.S. SOCOM, Army, and Navy, as well as several invitations specifically created for VAST testing and evaluation. Commercial Scale via Joint Venture (RMX and CRISP) Global Managed Services: RMXI partnered with K2 Endeavor DMCC to form RMX, a joint venture company building upon VAST and branded as 'CRISP' (Compressed Rate Intelligent Streaming Protocol) for commercial and enterprise verticals—from telecommunications to security camera networks. Recurring Revenue Model: RMX's global managed service structure is designed to offer predictable, long-term revenue while solving critical video-delivery challenges for enterprise customers. Expanded Product Suite VAST Video Encoder: The core software-based video encoder product will see the addition of key features including audio, KLV metadata support, video tele-conferencing, and region of interest encoding. VAST Vue: Cross-platform (Windows, Linux, Mac OS, Android, iOS) video player for seamless end-to-end experiences, including support for tactical metadata. VAST SDK: Development tools and APIs for advanced integration of core VAST capabilities into partner products and solutions. VAST VUDO: An advanced combination of VAST's video streaming capabilities with advanced mapping and sensor data integration to provide enhanced situational awareness in disconnected and austere environments. VAST Cloud: VAST-as-a-Service cloud offering for enterprise solutions, including live streaming, transcoding and VOD (video on demand) services. Acquisition of Remaining RMX Industries Inc. Shares to Consolidate Operations and Expand Leadership Team On April 23rd RMXI announced that it has acquired the remaining shares of RMX Industries Inc., the Company's 50/50 joint venture company with K2 Endeavor DMCC, through a stock exchange transaction, making it a wholly-owned subsidiary. The move consolidates operations and aligns resources to accelerate commercial business opportunities across key sectors. As part of this strategic consolidation, RMXI also announced important changes to its governance and management teams: Kirchof has been appointed as an independent member of the RMXI board of directors. Mr. Kirchof has over 20 years of experience building entrepreneurial companies and driving innovation in healthcare technology. Mr. Kirchof is the CEO of CureGrail, Inc., a healthcare technology company engaging and empowering patients to own and manage their disease, and founder and CEO of RxPath, LLC, a healthcare transaction company. Mr. Kirchof previously co-founded Matrix Oncology and served in executive, sales management, marketing, and strategy leadership positions at iKnowMed, Inc., MedStat Group, and IBM Healthcare. Karl Kit has been appointed as RMXI Chief Executive Officer, President and as a member of the board of directors. Mr. Kit is a seasoned entrepreneur with over 40 years of international business experience across advertising, communications, mobile data services, and financial technology. Mr. Kit previously headed K2 Endeavor DMCC, a UAE-based strategic investment group. Andrew Sheppard has been appointed as President of RMX Government. Mr. Sheppard will lead RMXI efforts in the defense and government sectors, focusing on deploying its cutting-edge video and data compression technologies to meet the mission-critical needs of military and public safety customers. Mr. Sheppard previously served as the Company's Chief Executive Officer and President. Maxwell Kit has been appointed as RMXI Chief Marketing Officer. Mr. Kit has extensive experience in global brand strategy, digital engagement, and go-to-market execution. As CMO, he will lead RMX's marketing and communications efforts, refine the RMXI brand identity, and expand market visibility. Mr. Kit will oversee the launch of integrated campaigns that highlight the transformative power of RMXI proprietary compression technology across defense, AI, telecommunications, and enterprise sectors. Opening of VAST Research & Testing Facility On March 17th RMXI announced the opening of its state-of-the-art VAST Research & Testing Facility (VRTF) outside of Rochester, NY. The facility covers dozens of acres and is capable of hosting real-life scenarios involving various tactical radio communication networks with manned/unmanned vehicles. RMXI expects the facility to accelerate the adoption of VAST's video compression technology by government programs and facilitate its uptake by tactical communications network vendors. VAST is a groundbreaking software-based video encoder platform, the first ever able to stream video over HF radio. Unlike traditional video encoder systems, VAST can operate on most x86 or Arm computing platform – from servers to low-SWaP (size, weight, and power) single-board computers. Its ability to enable video in bandwidth and resource-constrained tactical networks has opened a myriad of opportunities for video applications in scenarios and use cases where they were previously impossible. VAST Partner Program On March 3rd RMXI announced plans for its VAST Partner Program. The program will facilitate technology vendors and solution integrators to incorporate VAST's groundbreaking video compression technology into their products and offerings. The RMXI VAST Partner Program will include a dedicated partner manager who works closely with participants throughout the integration to commercialization process. Partners will receive engineering toolkits, demonstration resources, and technical consulting to accelerate time-to-market. The program will also offer early access to new features, input into product roadmaps, and collaborative marketing opportunities. Importantly, the program is available to all qualified companies interested in exploring VAST's capabilities. For more information on $RMXI visit DISCLAIMER: Disclosure listed on the CorporateAds website Media Contact Company Name: Reticulate Micro, Inc. Contact Person: Reticulate Micro Media Relations Email: Send Email Phone: 866-70 MICRO Address:4220 Duncan Ave, Suite 201 City: St. Louis State: Missouri 63110 Country: United States Website: Source: CAP, LLC
